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Abstract 
Purpose: To develop liposome formulations containing monoclonal antibody anti-HER2 (MabHer2), and 
Paclitaxel (PTX). 
Methods: Seven different liposomal systems containing PTX, or MabHer2 or a combination of PTX and 
MabHer2 were made using lipid film hydration technique and sonication. The effects of liposome 
preparation conditions and extraction methods on antibody structure were investigated by 
polyacrylamide gel electrophoresis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. The characteristics of the liposomes were determined by a zetasizer, while drug-loading 
efficiency was evaluated by high-performance liquid chromatography. The cytotoxic effect of the 
liposome formulations was evaluated on MDA-MB-453 (HER2+) and MCF-7 (HER2-) breast cancer cell 
lines by MTT assay.  
Results: The antibody was not significantly affected by the stress conditions and the method of 
extraction. The particle size of liposomes was < 200 nm while the amount of incorporated PTX was 97.6 
% for liposome without cationic agent and 98.2 % for those with cationic agent. Recovery of MabHer2 
was 94.38 % after extraction. Combined PTX/MabHer2 liposome was more toxic on HER2 
overexpressing positive MDA-MB-453 cell line than PTX-loaded liposomes and MabHer2. MabHer2 and 
combined PTX/MabHer2 liposomes showed no toxic effects on HER2 overexpressing negative MCF-7 
cells relative to cationic PTX-loaded liposomes. 
Conclusions: This results obtained show that PTX can be encapsulated successfully into liposomal 
systems and that owing to Her2 specific antibody, these systems can be delivered directly to the target 
cell.  
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Majority of the drugs used in cancer treatment 
have cytotoxic effects on both cancerous and 
normal cells. For this reason, conventional 
approaches for treatment of cancer and viral 
diseases are now giving way to smart drug 
delivery systems that minimize toxicity to normal 
cells, remain in circulation for longer periods and 
target specific cells [1]. 
  
PTX is one of the most important 
chemotherapeutic agents, usually administered 
via intravenous (IV) infusion. Due to its 
hydrophobic properties, it is usually formulated 
as 1:1 mixture with Cremophor EL or polyetoxy 
castor oil or alcohol. Cremophor EL is 
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incompatible with polyvinyl alcohol (PVA) and 
has toxic properties. These shortcomings limit 
the stability of infusion formulations, and render 
them toxic in clinical applications. 
 
PTX does not differentiate between cancerous 
and normal cells. Thus it has been suggested 
that localized and targeted PTX carrier systems 
need to be developed in order to reduce its 
toxicity and side effects [2]. Recent studies have 
shown that liposomal formulations of PTX and its 
derivatives were very effective in pre-clinical 
trials [3]. 
 
There are two major problems related with 
utilization of nanoparticles as drug carriers. First, 
nanoparticles cannot maintain their integrity 
during in vivo applications, so that the 
transported drug is released into circulation 
before it reaches the targeted site. Second, 
nanoparticles are captured by the cells of the 
reticuloendothelial system (RES) before reaching 
the targeted site [4]. To overcome these 
problems, cell-specific targeting studies have 
been conducted by binding antibodies to drug 
carrying vesicular systems [5]. 
 
Monoclonal antibodies directed against various 
target molecules are the most effective tools in 
cancer treatment today. High specificity and 
favorable toxicity profiles have placed these 
agents among standard treatment protocols 
despite their high costs [6]. Cancer cells and 
healthy cells have different anatomies and 
protein expressions [7]. The former often 
overexpress peptides, hormones and receptors 
for endocytosis of essential nutrients [8]. These 
receptors can be exploited for active and specific 
targeting for colloidal drug carriers. 
 
Humanized monoclonal antibody against 
HER2/ErbB-2 (human epidermal growth factor 
receptor 2/Neu), known as herceptin/trastzumab 
is a chemo-sensitizer widely used as an anti-
tumor agent in breast and ovary cancer [9]. 
The purpose of this study was to develop 
liposome formulations containing anti-HER2 







Phospholipon 85G® was used as a phospholipid 
and were purchased from Phospholipid GmbH 
(Köln, Germany). Anti-HER2 Antibody, Paclitaxel 
(from Taxus yannanensis, powder), were 
provided by Sigma-Aldrich (Hong Kong, China). 
While dichloromethane was obtained from 
Sigma-Aldrich (Steinheim, Germany), dimethyl-
sulfoxide (DMSO) was from Applichem 
(Darmstadt, Germany). Octadecylamine were 
purchased from Fluca (Darmstadt, Germany). 
 
Preparation of liposomes 
 
Liposomes were prepared using the modified 
method of lipid film hydration technique with 
sonication [10]. Phospholipon 85G® (40 mg) was 
dissolved in 1 mL dichloromethane (DCM) which 
was used as an organic phase in a round bottom 
glass flask. While rotating in Rotavapor (Buchi R-
205 Rotavapor, Switzerland) at 90-100 rpm on 
33 °C water bath, the organic solvent was 
removed under 250 mbar pressure, to form a 
lipid film layer on the inside surface of 5 mL the 
flask. After formation of lipid film, 2 mL aqueous 
phase (0.9 % NaCl, pH 7.4) was added, and the 
mixture was sonicated for 1.5 min at 20 % power 
using a sonicator (Sonics, USA) [11]. In the 
preparation of cationic liposome, octadecylamine 
(OCT) dissolved in organic phase was used as a 
cationic agent. Placebo liposome formulation 
was prepared without the addition of PTX.  
 
In the case of PTX loaded liposomes, OCT and 
PTX were dissolved in DCM as a lipid phase, 
and the liposomes were prepared as described 
above. To adsorb/load MabHer2 to formulations, 
the antibody was dispersed in the aqueous 
phase at predetermined concentration and added 
to the glass flask that included lipid(s) or 
lipid(s)/PTX mixture film, and sonicated [11]. 
Codes of the formulations and their proportions 
are given in Table 1. 
 
Evaluation of particle size and zeta potential 
 
Mean diameter of the bulk population and the 
particle distribution via the polydispersity index 
(PI) and zeta potentials of liposomes were 
analyzed by a Zetasizer NanoZS (Malvern 
Instruments, UK). Distilled water with a 
conductivity value of 50 μS/cm was adjusted 
using sodium chloride (0.1 N) at pH 7.4 and used 
in zeta potential analyses. Electrostatic mobility 
was converted to zeta potential using Helmholtz-
Smoluchowski equation. For the analyses 
constant amount (30 µL) of liposomes were 
dispersed in 1 mL of the distilled water and 
particle size, PI and zeta potentials were 
recorded (n=3). 
 
Determination of sonication effect on 
MabHer2 
 
The primary structure of the antibodies exposed  
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PS (nm)  PI  ZP (mV)  
LP 40 - - - 84.55 ± 5.30 0.277 ± 0.078 -36.90 ± 0.33 
LPO 40 1.2 - - 47.11 ± 3.72 0.567 ± 0.053 31.20 ± 0.79 
LPOH 40 1.2 - 1 179.01 ± 7.35 0.493 ± 0.672 13.45 ± 0.03 
LPX 40 - 3 - 198.21 ± 5.61 0.528 ± 0.712 -26.03 ± 0.98 
LPXH 40 - 3 1 189.32  ± 6.32 0.407 ± 0.820 -24.70 ± 1.03 
LPXO 40 1.2 3 - 172.76  ± 2.43 0.720 ± 0.232     4.71 ± 0.72 
LPXOH 40 1.2 3 1 165.35 ± 6.22 0.603 ± 1.023     5.35 ± 1.72 
Experiments were carried out in triplicates. PS; Particle size, PI; Polydispersity Index, ZP; Zeta potential and SE; 
Standard error 
 
to stress by sonication for different periods was 
determined using SDS-PAGE method [12].  
 
MabHer2 was dispersed in aqueous phase (0.9 
% NaCl, pH 7.4) at a formulation concentration of 
1 mg/mL, in a flask immersed in a temperature-
controlled (2 °C) water bath. The dispersions 
were sonicated for 10 min at 20 % power, and 
the procedure was paused to obtain 20 µL 
sample once every other minute. After the 10th 
minute, the procedure was paused once every 5 
min to obtain 2 more samples at the end of the 
20th minute. Each sample was added to 20 µL 
loading buffer (Laemmli 2X concentrate, Sigma-
Aldrich, USA), and then heated at 90 °C for 4 
min.  
 
The 20 µL sample obtained from the MabHer2 
dispersion prior to application of sonication 
procedure served as positive control. A 12 % 
polyacrylamide gel was prepared and the 
samples were applied on the gel in aliquots of 40 
µL. SDS–PAGE was performed on a vertical 
electrophoresis system (Cleaver Scientific, UK ) 
at a constant voltage of 150 V for about 3h. The 
gel was thereafter stained with coomassie blue 
and then de-stained in distilled water overnight. 
Images were obtained using Kodak Image 
Station 440CF (USA).  
 
MabHer2 extraction and quantitation 
 
Extraction method was used for isolation and 
quantitative determination of MabHer2 from 
LPXH and LPXOH formulations. A sample of 
each formulation (400 µL) was put in a micro 
tube, and 1 mL DCM was slowly added down the 
side of the tube.  The tube was slowly turned 
upside down to allow the lipid and PTX to 
dissolve in the organic solvent, and then 
centrifuged at 8000 rpm for 5 min.  The aqueous 
phase that contained the antibody was carefully 
removed, and its concentration was determined 
using nano-drop spectrophotometer (BioSpec-
Nano, Shimadzu, USA) by reading absorbance 
at 280 nm. Antibody extracted from LPXH was 
designated exLPXmab, and while that extracted 
from LPXOH was designated exLPXOHmab. 
 
Evaluation of effect of extraction method on 
MabHer2 
 
The effect of extraction method used on 
MabHer2 was determined with SDS-PAGE 
method. 10 µL of the extracted MabHer2s were 
mixed with 10 µL loading tampon, and loaded on 
to polyacrylamide gel as described above.  
 
Morphological characterization  
 
Morphological evaluation of nanoparticles is 
possible using scanning electron microscopy 
(SEM) and transmission electron microscopy 
(TEM) [13].  The morphological examination of 
the formulations was done using Carl Zeiss 
Microscopy (SUPRA 50VP model, Oberkochen, 
Germany). 
 
Liposomes (loaded with PTX or free) were 
dropped on the sampling chamber, and were 
allowed to dry at room-temperature. They were 
then coated to a thickness of approximately 100Å 
with gold, prior to the analyses. 
 
Quantitation of PTX  
 
High Performance Liquid Chromatography 
(HPLC) (20 A; Shimadzu Corporation, Tokyo, 
Japan) was used for quantitation of loaded PTX. 
Shimadzu Shim-Pack CLC-ODS column with a 
diameter of 6.0 mm and length of 15.0 cm was 
used.  The mobile phase was acetonitrile: 
distilled water (50: 50 v/v) mixture, at a flow rate 
of 1 mL/min.  For each sample, 20 µL was 
analyzed at 227 nm. Column temperature was 
set to 30 °C. Validation studies were performed 
for the reliability of data [14].  
 
In order to determine PTX content of the 
formulations, 500 µL of the formulation was 
mixed with 1.5 mL methanol and the mixture was 
filtered through a 0.22 µm pore size polyamide 
membrane filter. The filtrate (500 µL) was mixed 
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with 500 µL mobile phase and the HPLC 
analyses were performed. PTX content of the 
formulations was calculated according to Eq 1. 
 
E (%) = {(Di/Dt)}100 ………………………… (1) 
 
where Di and Dt are the incorporated and total 
drug, respectively. 
 
Evaluation of cytotoxicity 
 
Colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) method was 
used for the quantitative determination of  
cytotoxicity of the formulations on MDA-MB-453 
(HER2+) and MCF-7 (HER2-) breast cancer 
cells. The cells (2 × 104) were seeded in a 96-
well plate (Greiner, Sigma-Aldrich), and 
incubated at 37 °C for 24h in a humidified 
atmosphere containing 5 % CO2.  
 
The supernatant of each well was replaced with 
different concentrations of formulations, and the 
plates were incubated at 37 °C for 48 h, after 
which the supernatants were replaced with 20 µL 
of MTT dye (Greiner, Sigma-Aldrich, diluted with  
PBS  for  5  mg/mL concentration) solution. The 
plates were incubated for 4 h under the same 
conditions earlier mentioned.  
 
Then 200 µL spectrophotometric DMSO was 
then added to each well to dissolve the resultant 
formazan crystals. After 30 min of incubation, 
absorbance of the plates were measured at 570 
nm using a spectrometric microplate reader 
(Perkin Elmer Victor X5, England) [15]. 
 
Evaluation of effect of extraction method on 
MabHer2 activity 
 
In order to determine the effects of the extraction 
method on the antibody activity, different 
concentrations (1, 1.25, 1.5, 1.75, 2 and 2.5 
µg/100 µL) of MabHer2, exLPXHmab and 
exLPXOHmab were applied to MDA-MB-453 
(HER2+) cell lines, and their effectiveness was 




Characterization studies of liposomes  
 
The mean diameter, size distribution and zeta 
potential of the various liposomes are shown in 
Table 1. As the values show, incorporation of 
PTX into liposomes increased the size and 
decreased zeta potential of the liposomes. SEM 
images also confirm that particles were in the 





Figure 1: SEM images of LPO (a), LPOH (b), LPX 
(c),LPXO (d) and LPXOH (e) 
 
Efficacy of MabHer2s  
 
As Figure 2 – Figure 3 illustrates, no structural 
changes in antibodies between the native and 
the ultrasonicated MabHer2 solutions was found. 
Similarly, all bands of MabHer2s were in the 
same line and at similar concentrations. The 
concentration of the antibody obtained after 
extraction was 0.4719 ± 0.00695 µg/µL with the 
recovery rate of 94.38 %. 
 
Figure 2: SDS-PAGE gel image of native and 1-10, 15 




Linearity was evaluated within the 1-10 µg.mL-1 
range and the regression equation was 
determined as y = 19289x -1503 (r2 = 0.9999). 
The precision data were 1.5 and 2.0 % for 
repeatability and reproducibility respectively. 
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Accuracy of the method was calculated as 100.4 
± 0.5 %. Limit of detection (LOD) was found 21.0 
± 0.4 ng.mL-1, while limit of quantitation (LOQ) 
was 62 ± 0.8 ng.mL-1. The level of incorporated 
PTX in the LPX and LPXO formulations were 
calculated as 97.6 ± 0.3 and 98.2 ± 0.7 %, 
respectively with Eq 1. 
 
 
Figure 3: SDS-PAGE gel image of native (1), 
extracted from LPXH (2) and extracted LPXOH (3) 
MabHer2 solutions 
 
Cell viability  
 
The toxic effects of MabHer2 extracted from 
formulations (exLPXmab and exLPXOHmab) and 
native MabHer2 on MDA-MB-453 (HER2+) cell 
lines after 48 h were evaluated and the results 
are shown in Figure 4. The toxic values of Mabs 
exposed to cells at concentrations present in 
formulations were similar to each other (IC50, 2 
µL/100 µL). 
 
The toxicities of MabHer2 antibody, placebo 
liposome (LP and LPO), PTX-loaded and 
PTX/MabHer2-loaded formulations on both cell 




High-energy input such as elevated production 
temperature, high stirring rate, long 
emulsification time, and/or strong ultrasound 
power is required to breakdown the droplets into 
nanometer range [16]. However, it is known that 
the long sonication time applied for decreasing 
particle size and polydispersity index causes 
metal contamination [17]. In this study, particle 
sizes of LP and LPO formulations which did not 
contain PTX and MabHer2 were 84.55 and 47.11 
nm, respectively. As should be expected, 
increases in the particle sizes of LPX and LPXO 
were observed after addition of PTX (198 and 
172 nm). Formulations obtained via addition of 




Figure 4: Viability of MDA-MB-453 cells after being treated with native and extracted MabHer2 solutions. Each 
condition was tested in eight replicates for 48 h 
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Figure 5: Viability of MDA-MB-453 cells after being treated with MabHer2 solution and liposomes. Each condition 




Figure 6: Viability of MCF-7 cells after being treated with MabHer2 solution and liposomes. Each condition was 
tested in eight replicates for 48 h 
 
 (LPOH: 179 nm, LPXH: 189 nm and LPXOH: 
165 nm) also showed increase in size compared 
to LP and LPO formulations. However the sizes 
of these formulations remained smaller than 200 
nm.  
 
Delivery of tumor-targeted drugs takes 
advantage of the fact that malignant and normal 
tissue differ. Passive targeting can be achieved 
owing to the properties of blood vessels 
enfolding solid tumors, such as high permeability 
and high retention times for active ingredients; or 
by using localized applications. Depending on 
the tumor type, the gap between endothelial 
connections in solid tumors is approximately 300 
nm. This gap can be used for transport of the 
drugs to cancer cells. This phenomenon is 
known as EPR (enhanced permeability and 
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retention) effect. Many colloidal drug carrier 
systems make use of this effect, because the 
active ingredients stay longer in the blood 
circulation due to their small sizes [18]. Thus, the 
small particle size of the liposome-drug 
formulations seen in this study are consistent 
with EPR effect, which is desirable in cancer 
chemotherapy. 
 
Positively charged liposomes electrostatically 
interact with cellular membranes that have net 
negative charges. This interaction is important for 
the entry the active ingredient (whether drug or 
genetic material)-loaded liposomes into the cell 
[19]. Zeta potential of LP formulation increased 
from -36.90 mV to +31.20 mV on addition of the 
cationic agent, octadecylamine. Zeta potential of 
the liposomes have been observed to increase 
with increasing amount of octadecylamine [20]. 
The decrease in zeta potential of LPOH due to 
addition of MabHer2 to LPO may be attributed to 
surface charge of MabHer2 (+8.16 mV). This 
decrease is a clear evidence of the fact that 
MabHer2 was successfully attached onto the 
surface of liposome. Since LPO and MabHer2 
possess positive charges, the interaction 
between the antibody and the liposome was 
most likely due to hydrogen bonding and/or 
hydrophobic interaction [21]. 
 
In this study, SDS-PAGE was used to determine 
the structural changes in antibodies. Generally, 
ultrasound may be used as a tool to modify the 
biological, chemical and physical functionalities 
of proteins. Sulfhydryl groups, which are 
essential in protein configuration and function, 
are affected by sonication [22]. In addition, 
changes in temperature, pressure and voltage 
during sonication influence protein activity. 
Therefore, applied stress conditions and their 
effects should be determined for each protein 
[23].   
 
In this study, we tried to determine the 
appropriate sonication time in order to produce 
liposomes without negatively affecting the 
proteins. It was determined from the SDS-PAGE 
gel images that application of sonication for 20 
min while keeping ultrasound power constant (20 
kHz) did not disrupt the protein structure (Figure 
2). Since desired particle size (< 200 nm) was 
achieved with sonication for 1.5 min at 20 kHz 
power during preparation of liposomes without 
MabHer2, these sonication conditions were kept 
constant for all formulations. 
 
In order to determine the effects of formulation 
conditions on MabHer2, MabHer2 was extracted 
from LPXH (exLPXmab) and LPXOH 
(exLPXOHmab) using DCM. Organic solvents 
increase denaturation of proteins. It has been 
reported that protein deactivation depends on 
solubility of the organic solvent in the aqueous 
phase; these hydrophilic organic solvents can 
interact with accessible hydrophobic domains of 
the protein and disturb its structural integrity [24]. 
For this reason, DCM was used considering that 
its low aqueous solubility (S/mass is 1.73 %), 
and retained protein IgG in the presence of salt 
(approximately 97 %) [25]. The uniformity of the 
SDS-PAGE gel images indicate that the antibody 
protein structure was not denatured by 
fragmentation at any point [12].  
 
The cytotoxicity results indicate that 
effectiveness of MabHer2 was preserved during 
formulation and extraction steps, and that native 
MabHer2 had the same level of toxicity on MDA-
MD-453 cell line as exLPXmab and 
exLPXOHmab (Figure 4). This is proof MabHer2 
did not lose its structural properties, as confirmed 
by the results of SDS-PAGE analysis (Figure 3).  
 
LP formulation had no toxic effect on the cell 
lines. MabHer2 suspension at 2 µg/100 µL led to 
47 % viability in MDA-MB-453 (HER2+) cells; but 
as expected, it was not toxic to MCF-7 (HER2–) 
cells. LPO formulation, which contained 
octadecylamine in order to make it cationic, was 
more toxic compared to LP formulation especially 
on MCF-7 cells; however, it did not reduce cell 
viability below 50 %. 
 
LPX formulation showed toxicity on MDA-MD-
453 cells at 3.4 µL concentration. On MCF-7 
cells, it could not go below 50 % viability even at 
the highest concentration. This indicates that 
although LPX has cationic property, it was taken 
up by MDA-MD-453 cells. Since LPXO 
formulation was loaded with PTX and carries 
positive charge, its entry into cells was easier; 
thus it was more toxic on MCF-7 cells at lower 
concentrations (IC50, 3 µL/100 µL). LPXH 
formulation did not contain cationic agent but 
since MabHer2 was present, it showed toxic 
effect on MDA-MD-453 cells at 3 µL, unlike the 
MCF-7 cells. These results indicate that antibody 
can be attached/sinked onto liposomes, and after 
release it can inhibit cell proliferation via binding 
to Her2 receptors on MDA-MD-453 cells.  
 
Evaluation of LPOH formulation shows that it had 
a similar toxicity with LPO formulations. 
However, while LPO formulation did not show 
toxicity on MDA-MD-453 cells even at highest 
concentrations, LPOH formulation decreased 
viability down to 37 % at 4 µL concentration. This 
shows that antibody was loaded on the 
formulations and inhibited cell proliferation via 
acting on Her2 receptor. LPXOH formulation 
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showed toxicity on MDA-MD-453 cells at 1 µL 
concentration. When compared with the toxicity 
of LPXO formulation, the reduction in cell viability 
below 50 % at lowest dose (1 µL) suggests 
binding of LPXOH formulation to MDA-MD-453 
via the antibody and increased uptake. It can 
also be a consequence of synergism between 
the ability of the antibody to inhibit cell 
proliferation via binding to Her2 receptor, and the 
toxicity of PTX. LPXO formulation was the most 
toxic formulation on MCF-7 cells. 
 
However, LPXOH formulation prepared with 
MabHer2 was not cytotoxic. Addition of MabHer2 
to LPXO formulation caused a decrease in zeta 
potential, and this resulted in reduced attachment 
ability of the particles on the cell surfaces. As a 
result, LPXO formulation (IC50, 3 µL/100 µL) was 
the most toxic formulation on MCF-7 (HER2–) 
cells while LPXOH formulation (IC50 : 1 µL/100 
µL) was the most toxic formulation on MDA-MD-




The findings of this study show that MabHer2 
can be attached/linked to cationic and anionic 
PTX-loaded liposomes, and that PTX/MabHer2 
liposomes increased toxicity in HER2 
overexpressed MDA-MD-453 breast cancer cell 
line. Since stress conditions applied during the 
preparation of the systems has no adverse effect 
on the structure of antibodies, it is seems that an 
antibody attached/linked colloidal drug carrier 
system (provided that stability optimization is 
performed) can be prepared with ease and at a 
low cost, without the need for chemical reaction 
such as biotinylation or procedures for coating 
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